AI assistant
AVADEL PHARMACEUTICALS PLC — Director's Dealing 2019
Aug 9, 2019
31920_dirs_2019-08-09_2519f3d2-9141-42aa-8f55-0dff20ce2754.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: AVADEL PHARMACEUTICALS PLC (AVDL)
CIK: 0001012477
Period of Report: 2019-08-07
Reporting Person: Palczuk Linda (Director)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2019-08-07 | Stock Option (right to buy) | $2.03 | A | 60000 | Acquired | 2029-08-07 | ADSs (60000) | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| ADSs | 27900 | Direct |
Footnotes
F1: The issuer's "ADSs" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts.
F2: Represents 27,900 restricted ADSs granted under the issuer's Omnibus Incentive Compensation Plan on 08/01/2018; one-third (1/3) of the ADSs will vest on each of the first three anniversaries of the grant date.
F3: Options become exercisable as to 20,000 ADSs on each of the first three anniversaries after the 08/07/2019 grant date.